Previous 10 | Next 10 |
IDEAYA Biosciences (IDYA) has priced its public offering of 4,637,681 common shares at $17.25/share, for expected gross proceeds of ~$80M.Underwriters' over-allotment is an additional 695,652 shares. Net proceeds will be used to fund preclinical and clinical development of product candid...
Newegg Commerce (NEGG) +115%.Dare Bioscience (DARE) +35%.Opiant Pharmaceuticals (OPNT) +32%.Data Storage (DTST) +32%.OncoSec Medical (ONCS) +30%.Peabody Energy (BTU) +27%.iPower (IPW) +21%.SMART Global Holdings (SGH) +20%.Virpax Pharmaceuticals (VRPX) +18%.X Financial...
Gainers: Virpax Pharmaceuticals (VRPX) +46%. Opiant Pharmaceuticals (OPNT) +31%. OncoSec Medical (ONCS) +24%. Dare Bioscience (DARE) +18%. Biohaven Pharmaceutical Holding Company (BHVN) +12%.Losers: IDEAYA Biosciences (IDYA) -24%. Cleveland BioLabs (CBLI) -20%. Soligenix (SNGX) -16%...
Mikhail Leonov/iStock via Getty Images Funding in the biotech space led to a couple of major advances in Wednesday's pre-market. OncoSec (ONCS) rallied on news of a collaboration deal with Merck (MRK). Daré Bioscience (DARE) also gained ground before the bell, thanks to a grant from the ...
IDEAYA Biosciences (IDYA) to offer and sell up to $80M shares of its common stock in an underwritten public offering. Underwriters' 30-day option to purchase up to $12M shares.Size and terms not yet finalized.Net proceeds, along with its existing cash, cash equivalents and short-ter...
These July selections are the current top positive and negative forensic stocks based on combined scores from four different forensic algorithms. The past 5 Negative Forensic portfolios have returned: Jan 2021 +16.7%, July 2020: +114.1%, Feb 2020: +64.9%, Dec 2019: +59.0%, Oct 2019: +...
IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination ‒ Observed plasma SAM reduction in each of the first two dose escalation cohorts of the IDE397 Phase 1 clinical trial, satisfying the clinical p...
IDEAYA Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , May 24, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company co...
IDEAYA Biosciences (IDYA): Q1 GAAP EPS of -$0.28 beats by $0.01.Revenue of $7.2M misses by $0.28M.Cash, cash equivalents and marketable securities of $310.4MPress Release For further details see: IDEAYA Biosciences EPS beats by $0.01, misses on revenue
IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort - Observed early clinical efficacy in first cohort of darovasertib plus crizotinib combination with tumor reduction in 2 of ...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...
2024-07-08 17:30:03 ET BTIG analyst issues BUY recommendation for IDYA on July 8, 2024 03:52PM ET. The previous analyst recommendation was Buy. IDYA was trading at $39.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...